Flare Therapeutics

Cambridge, United States

Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.

$123.0M raised

Mar 2023

Series B

Biopharma Biotechnology Health Care Life Science Neuroscience

Top Investors

Eli Lilly Novartis Invus Casdin Capital Pfizer Venture Investments

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Flare Therapeutics

How much funding has Flare Therapeutics raised?

Flare Therapeutics has raised $123.0M in total funding. The most recent round was Series B. The last funding was announced in March 2023.

Who are Flare Therapeutics's investors?

Flare Therapeutics's investors include Eli Lilly, Novartis, Invus, Casdin Capital, Pfizer Venture Investments.

Where is Flare Therapeutics headquartered?

Flare Therapeutics is headquartered in Cambridge, United States.

What does Flare Therapeutics do?

Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.

What stage is Flare Therapeutics at?

Flare Therapeutics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 22, 2023.

MLA

"Flare Therapeutics — Funding & Investors." VCBacked, March 22, 2023, https://www.vcbacked.co/company/flare-therapeutics. Accessed July 2, 2026.

APA

VCBacked. (2023). Flare Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/flare-therapeutics

Wikipedia (cite web)

{{cite web |title=Flare Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/flare-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 22, 2023.

Similar Companies in Biopharma

View all

Allterum Therapeutics

Living In Silico Inc.